{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:46:11Z","timestamp":1786121171783,"version":"build-2736575974"},"reference-count":130,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.autrev.2026.104121","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:14:43Z","timestamp":1781136883000},"page":"104121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting shared immune pathways in multiple sclerosis and type 1 diabetes: Therapeutic insights from monoclonal antibodies"],"prefix":"10.1016","volume":"25","author":[{"given":"Valeria","family":"Pozzilli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Aurora","family":"Roma-Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Pozzilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Buzzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2026.104121_bb0005","doi-asserted-by":"crossref","unstructured":"Abdel-Moneim A, Bakery HH, Allam G. The potential pathogenic role of IL-17\/Th17 cells in both type 1 and type 2 diabetes mellitus. Biomed Pharmacother 2018 101:287\u201392. doi:https:\/\/doi.org\/10.1016\/j.biopha.2018.02.103 [PubMed PMID: 29499402].","DOI":"10.1016\/j.biopha.2018.02.103"},{"key":"10.1016\/j.autrev.2026.104121_bb0010","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1146\/annurev-pathol-052920-040318","article-title":"The immune response in multiple sclerosis","volume":"17","author":"Rodr\u00edguez Mur\u00faa","year":"2022","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104121_bb0015","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3505","article-title":"Similarities and differences between multiple sclerosis and type 1 diabetes","volume":"38","author":"Pozzilli","year":"2022","journal-title":"Diabetes Metab Res Rev"},{"issue":"7","key":"10.1016\/j.autrev.2026.104121_bb0020","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/archneur.63.7.1001","article-title":"Type 1 diabetes and multiple sclerosis: a Danish population-based cohort study","volume":"63","author":"Nielsen","year":"2006","journal-title":"Arch Neurol"},{"issue":"9316","key":"10.1016\/j.autrev.2026.104121_bb0025","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/S0140-6736(02)08431-3","article-title":"Patients with multiple sclerosis and risk of type 1 diabetes mellitus in Sardinia, Italy: a cohort study","volume":"359","author":"Marrosu","year":"2002","journal-title":"Lancet"},{"issue":"7539","key":"10.1016\/j.autrev.2026.104121_bb0030","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature13835","article-title":"Genetic and epigenetic fine mapping of causal autoimmune disease variants","volume":"518","author":"Farh","year":"2015","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.autrev.2026.104121_bb0035","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40265-024-02011-w","article-title":"Drugs targeting CD20 in multiple sclerosis: pharmacology, efficacy, safety, and tolerability","volume":"84","author":"Carlson","year":"2024","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.autrev.2026.104121_bb0040","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.2337\/dc23-0675","article-title":"Teplizumab: a disease-modifying therapy for type 1 diabetes that preserves \u03b2-cell function","volume":"46","author":"Herold","year":"2023","journal-title":"Diabetes Care"},{"key":"#cr-split#-10.1016\/j.autrev.2026.104121_bb0045.1","unstructured":"Sanofi 2025. A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis [Clinical Trial Registration] [Internet]. clinicaltrials.gov"},{"key":"#cr-split#-10.1016\/j.autrev.2026.104121_bb0045.2","unstructured":"2025 Oct [cited 2025 Nov 17]. Clinical trial registration no.: NCT06141486. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06141486."},{"key":"10.1016\/j.autrev.2026.104121_bb0050","author":"Sanofi"},{"key":"#cr-split#-10.1016\/j.autrev.2026.104121_bb0055.1","unstructured":"Sanofi 2025. A 52-Week Randomized, Double-Blind, Placebo-Controlled, Multi-center Phase 2b Study With a 52-week Blinded Extension Assessing Safety and Efficacy of Frexalimab, a CD40L-antagonist Monoclonal Antibody, for Preservation of Pancreatic \u03b2-cell Function in Adults and Adolescents With Newly Diagnosed Type 1 Diabetes on Insulin Therapy [Clinical Trial Registration] [Internet]. clinicaltrials.gov"},{"key":"#cr-split#-10.1016\/j.autrev.2026.104121_bb0055.2","unstructured":"2025 Oct [cited 2025 Nov 17]. Clinical Trial Registration no.: NCT06111586. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06111586."},{"issue":"1","key":"10.1016\/j.autrev.2026.104121_bb0060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/gene.2008.83","article-title":"International multiple sclerosis genetics consortium (IMSGC). The expanding genetic overlap between multiple sclerosis and type I diabetes","volume":"10","year":"2009","journal-title":"Genes Immun"},{"issue":"3","key":"10.1016\/j.autrev.2026.104121_bb0065","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.4049\/jimmunol.175.3.1558","article-title":"CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions","volume":"175","author":"Dardalhon","year":"2005","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104121_bb0070","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10048-008-0156-y","article-title":"Risk for multiple sclerosis in relatives and spouses of patients diagnosed with autoimmune and related conditions","volume":"10","author":"Hemminki","year":"2009","journal-title":"Neurogenetics"},{"issue":"9","key":"10.1016\/j.autrev.2026.104121_bb0075","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa073493","article-title":"Risk alleles for multiple sclerosis identified by a genomewide study","volume":"357","author":"International Multiple Sclerosis Genetics Consortium","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104121_bb0080","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s12020-019-02181-8","article-title":"Identification of common key genes and pathways between type 1 diabetes and multiple sclerosis using transcriptome and interactome analysis","volume":"68","author":"Safari-Alighiarloo","year":"2020","journal-title":"Endocrine"},{"issue":"11","key":"10.1016\/j.autrev.2026.104121_bb0085","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.2337\/diacare.26.11.3192","article-title":"Type 1 diabetes and multiple sclerosis: together at last","volume":"26","author":"Dorman","year":"2003","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.autrev.2026.104121_bb0090","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028944","article-title":"Lifestyle and environmental factors in multiple sclerosis","volume":"9","author":"Alfredsson","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"6","key":"10.1016\/j.autrev.2026.104121_bb0095","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jcjd.2016.05.002","article-title":"Environmental risk factors and type 1 diabetes: past, present, and future","volume":"40","author":"Butalia","year":"2016","journal-title":"Can J Diabetes"},{"issue":"3","key":"10.1016\/j.autrev.2026.104121_bb0100","first-page":"160","article-title":"Epstein\u2013Barr virus as a leading cause of multiple sclerosis: mechanisms and implications","volume":"19","author":"Bjornevik","year":"2023","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104121_bb0105","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1210\/endrev\/bnad007","article-title":"Coxsackievirus and type 1 diabetes: diabetogenic mechanisms and implications for prevention","volume":"44","author":"Carr\u00e9","year":"2023","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.autrev.2026.104121_bb0110","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.1016\/j.autrev.2026.104121_bb0115","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.4049\/jimmunol.166.4.2831","article-title":"Type I diabetes and multiple sclerosis patients target islet plus central nervous system autoantigens; nonimmunized nonobese diabetic mice can develop autoimmune encephalitis","volume":"166","author":"Winer","year":"2001","journal-title":"J Immunol"},{"issue":"10422","key":"10.1016\/j.autrev.2026.104121_bb0120","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0140-6736(23)01473-3","article-title":"Multiple sclerosis","volume":"403","author":"Jakimovski","year":"2024","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.autrev.2026.104121_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112359","article-title":"Shed light on molecular immunogenetic pathophysiology of type 1 diabetes to improve advanced treatment strategies","volume":"226","author":"Moosavi","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"10.1016\/j.autrev.2026.104121_bb0130","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S1474-4422(21)00063-6","article-title":"Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances","volume":"20","author":"Bar-Or","year":"2021","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.autrev.2026.104121_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102647","article-title":"The role of TH17 cells in multiple sclerosis: therapeutic implications","volume":"19","author":"Moser","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.autrev.2026.104121_bb0140","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.coi.2011.08.004","article-title":"CD4 T cells and their antigens in the pathogenesis of autoimmune diabetes","volume":"23","author":"Haskins","year":"2011","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104121_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/cells9020482","article-title":"T helper cells: the modulators of inflammation in multiple sclerosis","volume":"9","author":"Kunkl","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.autrev.2026.104121_bb0150","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4049\/jimmunol.1401653","article-title":"Th1\/Th17 plasticity is a marker of advanced \u03b2 cell autoimmunity and impaired glucose tolerance in humans","volume":"194","author":"Reinert-Hartwall","year":"2015","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104121_bb0155","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1172\/JCI132531","article-title":"Myelin-specific CD8+ T cells exacerbate brain inflammation in CNS autoimmunity","volume":"130","author":"Wagner","year":"2020","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.autrev.2026.104121_bb0160","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00109-009-0516-6","article-title":"The primacy of CD8 T lymphocytes in type 1 diabetes and implications for therapies","volume":"87","author":"Faustman","year":"2009","journal-title":"J Mol Med Berl Ger"},{"issue":"3","key":"10.1016\/j.autrev.2026.104121_bb0165","doi-asserted-by":"crossref","first-page":"752","DOI":"10.2337\/db20-0908","article-title":"One in ten CD8+ cells in the pancreas of living individuals with recent-onset type 1 diabetes recognizes the Preproinsulin epitope PPI15-24","volume":"70","author":"Rodriguez-Calvo","year":"2021","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.autrev.2026.104121_bb0170","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12974-019-1517-1","article-title":"Impact of B cells to the pathophysiology of multiple sclerosis","volume":"16","author":"Arneth","year":"2019","journal-title":"J Neuroinflammation"},{"issue":"3","key":"10.1016\/j.autrev.2026.104121_bb0175","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.autrev.2026.104121_bb0180","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a041593","article-title":"The role of B lymphocytes in type 1 diabetes","volume":"15","author":"Smith","year":"2025","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104121_bb0185","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2337\/db13-1639","article-title":"Interleukin-10+ regulatory B cells arise within antigen-experienced CD40+ B cells to maintain tolerance to islet autoantigens","volume":"64","author":"Kleffel","year":"2015","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.autrev.2026.104121_bb0190","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1084\/jem.20031579","article-title":"Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis","volume":"199","author":"Viglietta","year":"2004","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.autrev.2026.104121_bb0195","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nri2889","article-title":"Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases","volume":"10","author":"Buckner","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"416","key":"10.1016\/j.autrev.2026.104121_bb0200","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7543","article-title":"PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes","volume":"9","author":"Ben Nasr","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2026.104121_bb0205","doi-asserted-by":"crossref","unstructured":"Evans-Molina C, Sims EK, DiMeglio LA, Ismail HM, Steck AK, Palmer JP, et al. \u03b2 Cell dysfunction exists more than 5 years before type 1 diabetes diagnosis. JCI Insight 3(15):e120877. doi:https:\/\/doi.org\/10.1172\/jci.insight.120877 PubMed PMID: 30089716; PubMed Central PMCID: PMC6129118.","DOI":"10.1172\/jci.insight.120877"},{"key":"10.1016\/j.autrev.2026.104121_bb0210","first-page":"11","article-title":"Evolving antibody therapies for the treatment of type 1 diabetes","volume":"18","author":"Ke","year":"2021","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.autrev.2026.104121_bb0215","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.2337\/db24-0163","article-title":"Revisiting the pattern of loss of \u03b2-cell function in preclinical type 1 diabetes","volume":"73","author":"Martino","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2026.104121_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104789","article-title":"Cross-talk between B cells, microglia and macrophages, and implications to central nervous system compartmentalized inflammation and progressive multiple sclerosis","volume":"96","author":"Touil","year":"2023","journal-title":"EBioMedicine"},{"issue":"17","key":"10.1016\/j.autrev.2026.104121_bb0225","doi-asserted-by":"crossref","first-page":"e1783","DOI":"10.1212\/WNL.0000000000200144","article-title":"Association of slowly expanding lesions on MRI with disability in people with secondary progressive multiple sclerosis","volume":"98","author":"Calvi","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2026.104121_bb0230","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2025.2619","article-title":"Slowly expanding lesions in pediatric-onset multiple sclerosis","author":"Pozzilli","year":"2025","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104121_bb0235","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200506","article-title":"Paramagnetic rim lesions in pediatric multiple sclerosis and their association with brain tissue atrophy","volume":"13","author":"Nistri","year":"2026","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"10.1016\/j.autrev.2026.104121_bb0240","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.autrev.2026.104121_bb0245","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1210\/clinem\/dgaf194","article-title":"Establishing screening programs for Presymptomatic type 1 diabetes: practical guidance for diabetes care providers","volume":"110","author":"Leichter","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.autrev.2026.104121_bb0250","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","article-title":"Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria","volume":"24","author":"Montalban","year":"2025","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104121_bb0255","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s40265-018-1035-y","article-title":"Disease-modifying therapies in type 1 diabetes: a look into the future of diabetes practice","volume":"79","author":"Greenbaum","year":"2019","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.autrev.2026.104121_bb0260","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3770","article-title":"Type 1 diabetes: a new vision of the disease based on endotypes","volume":"40","author":"Weston","year":"2024","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.autrev.2026.104121_bb0265","article-title":"Corrigendum to \u2018What type 1 diabetes endotype is most suitable for anti-CD3 antibodies prevention trials?\u2019 [JDC, Vol. 39, Issue 10, October 2025, 109132]","author":"Roma-Wilson","year":"2025","journal-title":"J Diabetes Complicat"},{"issue":"1","key":"10.1016\/j.autrev.2026.104121_bb0270","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-022-00390-6","article-title":"Adult-onset autoimmune diabetes","volume":"8","author":"Buzzetti","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"10.1016\/j.autrev.2026.104121_bb0275","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3536","article-title":"Unveiling a novel type 1 diabetes endotype: opportunities for intervention","volume":"38","author":"Fiorina","year":"2022","journal-title":"Diabetes Metab Res Rev"},{"issue":"6","key":"10.1016\/j.autrev.2026.104121_bb0280","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00125-020-05115-6","article-title":"Studies of insulin and proinsulin in pancreas and serum support the existence of aetiopathological endotypes of type 1 diabetes associated with age at diagnosis","volume":"63","author":"Leete","year":"2020","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.autrev.2026.104121_bb0285","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41574-023-00853-0","article-title":"Heterogeneity and endotypes in type 1 diabetes mellitus","volume":"19","author":"Redondo","year":"2023","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104121_bb0290","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00125-012-2753-4","article-title":"Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial","volume":"56","author":"Herold","year":"2013","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.autrev.2026.104121_bb0295","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An anti-CD3 antibody, Teplizumab, in relatives at risk for type 1 diabetes","volume":"381","author":"Herold","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.autrev.2026.104121_bb0300","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1007\/s00125-023-06003-5","article-title":"High proinsulin:C-peptide ratio identifies individuals with stage 2 type 1 diabetes at high risk for progression to clinical diagnosis and responses to teplizumab treatment","volume":"66","author":"Sims","year":"2023","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.autrev.2026.104121_bb0305","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41435-018-0032-1","article-title":"Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes","volume":"20","author":"Linsley","year":"2019","journal-title":"Genes Immun"},{"issue":"22","key":"10.1016\/j.autrev.2026.104121_bb0310","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","article-title":"Rituximab, B-lymphocyte depletion, and preservation of beta-cell function","volume":"361","author":"Pescovitz","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.autrev.2026.104121_bb0315","doi-asserted-by":"crossref","first-page":"22","DOI":"10.17925\/EE.2023.19.2.7","article-title":"Teplizumab in type 1 diabetes mellitus: an updated review","volume":"19","author":"Thakkar","year":"2023","journal-title":"TouchREVIEWS Endocrinol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104121_bb0320","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.autrev.2026.104121_bb0325","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1474-4422(07)70196-5","article-title":"Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study","volume":"6","author":"Banwell","year":"2007","journal-title":"Lancet Neurol"},{"issue":"17_supplement_2","key":"10.1016\/j.autrev.2026.104121_bb0330","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1212\/WNL.0000000000202658","article-title":"Real-world effectiveness of ocrelizumab in a multi-centre pediatric-onset multiple sclerosis (POMS) cohort in the United Kingdom (S31.007)","volume":"100","author":"Abdel-Mannan","year":"2023","journal-title":"Neurology"},{"issue":"13","key":"10.1016\/j.autrev.2026.104121_bb0335","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1177\/1352458520937644","article-title":"What does first-line therapy mean for paediatric multiple sclerosis in the current era?","volume":"27","author":"Hacohen","year":"2021","journal-title":"Mult Scler"},{"issue":"740","key":"10.1016\/j.autrev.2026.104121_bb0340","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ade8560","article-title":"Multiple sclerosis endophenotypes identified by high-dimensional blood signatures are associated with distinct disease trajectories","volume":"16","author":"Gross","year":"2024","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.autrev.2026.104121_bb0345","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1212\/CPJ.0000000000001045","article-title":"Multiple sclerosis phenotypes as a continuum","volume":"11","author":"Vollmer","year":"2021","journal-title":"Neurol Clin Pract"},{"issue":"8","key":"10.1016\/j.autrev.2026.104121_bb0350","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.autrev.2026.104121_bb0355","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa2415988","article-title":"Tolebrutinib in nonrelapsing secondary progressive multiple sclerosis","volume":"392","author":"Fox","year":"2025","journal-title":"N Engl J Med"},{"issue":"118","key":"10.1016\/j.autrev.2026.104121_bb0360","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003401","article-title":"Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients","volume":"4","author":"Waldron-Lynch","year":"2012","journal-title":"Sci Transl Med"},{"issue":"23","key":"10.1016\/j.autrev.2026.104121_bb0365","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa2308743","article-title":"Teplizumab and \u03b2-cell function in newly diagnosed type 1 diabetes","volume":"389","author":"Ramos","year":"2023","journal-title":"N Engl J Med"},{"issue":"583","key":"10.1016\/j.autrev.2026.104121_bb0370","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc8980","article-title":"Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals","volume":"13","author":"Sims","year":"2021","journal-title":"Sci Transl Med"},{"issue":"Supplement_1","key":"10.1016\/j.autrev.2026.104121_bb0375","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.2337\/dc25-S003","article-title":"3. Prevention or delay of diabetes and associated comorbidities: standards of Care in Diabetes\u20142025","volume":"48","author":"American Diabetes Association pProfessional pPractice cCommittee","year":"2024","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.autrev.2026.104121_bb0380","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12933-025-02696-7","article-title":"Anti-CD3 monoclonal antibody in treating patients with type 1 diabetes: an updated systematic review and meta-analysis","volume":"24","author":"Wu","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.autrev.2026.104121_bb0385","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cellimm.2017.07.007","article-title":"Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes","volume":"319","author":"Long","year":"2017","journal-title":"Cell Immunol"},{"key":"10.1016\/j.autrev.2026.104121_bb0390","author":"Neurology Live [Internet]"},{"key":"10.1016\/j.autrev.2026.104121_bb0395","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.956907","article-title":"Nasal administration of anti-CD3 monoclonal antibody modulates effector CD8+ T cell function and induces a regulatory response in T cells in human subjects","volume":"13","author":"Chitnis","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104121_bb0400","author":"Tiziana Life Sciences LTD"},{"issue":"2","key":"10.1016\/j.autrev.2026.104121_bb0405","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200543","article-title":"Nasal Foralumab for the treatment of progression independent of relapses in patients with nonactive secondary progressive multiple sclerosis","volume":"13","author":"Chitnis","year":"2026","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.autrev.2026.104121_bb0410","author":"Tiziana Life Sciences LTD"},{"issue":"1","key":"10.1016\/j.autrev.2026.104121_bb0415","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s13317-017-0100-y","article-title":"Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment","volume":"8","author":"Du","year":"2017","journal-title":"Autoimmun Highlights"},{"key":"10.1016\/j.autrev.2026.104121_bb0420","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1004795","article-title":"Anti-CD20 therapies in multiple sclerosis: from pathology to the clinic","volume":"14","author":"de S\u00e8ze","year":"2023","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104121_bb0425","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1080\/21645515.2018.1508624","article-title":"Anti-CD20 monoclonal antibodies: reviewing a revolution","volume":"14","author":"Casan","year":"2018","journal-title":"Hum Vaccin Immunother"},{"issue":"9","key":"10.1016\/j.autrev.2026.104121_bb0430","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s40263-021-00843-8","article-title":"Clinical perspectives on the molecular and pharmacological attributes of anti-CD20 therapies for multiple sclerosis","volume":"35","author":"Bar-Or","year":"2021","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1016\/j.autrev.2026.104121_bb0435","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/biomedicines11061610","article-title":"Mechanisms of action and limitations of monoclonal antibodies and single chain fragment variable (scFv) in the treatment of cancer","volume":"11","author":"Rodr\u00edguez-Nava","year":"2023","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/j.autrev.2026.104121_bb0440","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/brainsci10100758","article-title":"Anti-CD20 agents for multiple sclerosis: spotlight on Ocrelizumab and Ofatumumab","volume":"10","author":"Florou","year":"2020","journal-title":"Brain Sci"},{"issue":"3","key":"10.1016\/j.autrev.2026.104121_bb0445","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.autrev.2026.104121_bb0450","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus Teriflunomide in Multiple Sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.autrev.2026.104121_bb0455","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMoa2201904","article-title":"Ublituximab versus Teriflunomide in relapsing multiple sclerosis","volume":"387","author":"Steinman","year":"2022","journal-title":"N Engl J Med"},{"issue":"76","key":"10.1016\/j.autrev.2026.104121_bb0460","first-page":"1","article-title":"Anti-CD20 therapy ameliorates \u03b2 cell function and rebalances Th17\/Treg cells in NOD mice","author":"Chen","year":"2022","journal-title":"Endocrine"},{"issue":"8","key":"10.1016\/j.autrev.2026.104121_bb0465","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.2337\/db12-1175","article-title":"Combination treatment with anti-CD20 and Oral anti-CD3 prevents and reverses autoimmune diabetes","volume":"62","author":"Hu","year":"2013","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.autrev.2026.104121_bb0470","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2337\/dc13-0626","article-title":"B-lymphocyte depletion with rituximab and \u03b2-cell function: two-year results","volume":"37","author":"Pescovitz","year":"2014","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.autrev.2026.104121_bb0475","first-page":"64","article-title":"Narrative review of anti-CD3 antibody and anti-CD20 antibody: immunotherapeutic strategies to treat and prevent type 1 diabetes","volume":"17","author":"Kashalikar","year":"2023","journal-title":"Recent Adv Inflamm Allergy Drug Discov"},{"issue":"4","key":"10.1016\/j.autrev.2026.104121_bb0480","doi-asserted-by":"crossref","DOI":"10.20517\/mtod.2024.37","article-title":"Immunotherapy for type 1 diabetes","volume":"4","author":"Sann","year":"2024","journal-title":"Metab Target Organ Damage"},{"issue":"12","key":"10.1016\/j.autrev.2026.104121_bb0485","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010059","article-title":"CD40L protects against mouse hepatitis virus-induced neuroinflammatory demyelination","volume":"17","author":"Saadi","year":"2021","journal-title":"PLoS Pathog"},{"issue":"3\u20134","key":"10.1016\/j.autrev.2026.104121_bb0490","first-page":"69","article-title":"CD40\/CD40 ligand interactions in immune responses and pulmonary immunity","volume":"73","author":"Kawabe","year":"2011","journal-title":"Nagoya J Med Sci"},{"key":"10.1016\/j.autrev.2026.104121_bb0495","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01791","article-title":"The CD40\u2013CD40L dyad in experimental autoimmune encephalomyelitis and multiple sclerosis","volume":"8","author":"Aarts","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104121_bb0500","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.addr.2018.12.005","article-title":"Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond","author":"Karnell","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.autrev.2026.104121_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00558","article-title":"Therapeutic advances in multiple sclerosis: novel therapies (immune checkpoint inhibitors, CAR-T, anti-CD40L)","author":"Conway","year":"2025","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.autrev.2026.104121_bb0510","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11940-024-00818-2","article-title":"Inhibiting CD40 ligand in multiple sclerosis: a review of emerging therapeutic potential","volume":"27","author":"Vermersch","year":"2024","journal-title":"Curr Treat Options Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104121_bb0515","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004613","article-title":"TLR3 signaling in macrophages is indispensable for the protective immunity of invariant natural killer T cells against enterovirus 71 infection","volume":"11","author":"Zhu","year":"2015","journal-title":"PLoS Pathog"},{"issue":"1","key":"10.1016\/j.autrev.2026.104121_bb0520","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/1471-2334-12-327","article-title":"Differential apoptosis gene expressions of rhabdomyosarcoma cells in response to enterovirus 71 infection","volume":"12","author":"Shi","year":"2012","journal-title":"BMC Infect Dis"},{"issue":"7","key":"10.1016\/j.autrev.2026.104121_bb0525","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2309439","article-title":"Inhibition of CD40L with Frexalimab in multiple sclerosis","volume":"390","author":"Vermersch","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104121_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.106111","article-title":"Frexalimab in relapsing multiple sclerosis and non-relapsing secondary progressive multiple sclerosis: design of phase 3 frexalt and freviva trials","volume":"92","author":"Krieger","year":"2024","journal-title":"Mult Scler Relat Disord"},{"issue":"Supplement_1","key":"10.1016\/j.autrev.2026.104121_bb0535","doi-asserted-by":"crossref","DOI":"10.2337\/db24-2021-LB","article-title":"FABULINUS\u2014A randomized, controlled trial with FrexalimAB, to assess endogenous insulin secretion in new-onset stage 3 type 1 diabetes adults and adolescents","volume":"73","author":"Haller","year":"2024","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.autrev.2026.104121_bb0540","first-page":"14","article-title":"Efficacy of immunosuppression in preserving beta cell function and reducing insulin requirements in type 1 diabetes mellitus: a comprehensive review","volume":"30","author":"Pillay","year":"2025","journal-title":"J Endocrinol Metab Diabetes S Afr"},{"issue":"6","key":"10.1016\/j.autrev.2026.104121_bb0545","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/CRD.0000000000000563","article-title":"Teplizumab therapy to delay the onset of type 1 diabetes","volume":"32","author":"Novograd","year":"2024","journal-title":"Cardiol Rev"},{"issue":"8","key":"10.1016\/j.autrev.2026.104121_bb0550","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.4239\/wjd.v15.i8.1793","article-title":"Safety of teplizumab in patients with high-risk for diabetes mellitus type 1: a systematic review","volume":"15","author":"Buddhavarapu","year":"2024","journal-title":"World J Diabetes"},{"issue":"2","key":"10.1016\/j.autrev.2026.104121_bb0555","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s12020-023-03499-0","article-title":"Anti-CD3 monoclonal antibodies in treatment of type 1 diabetes: a systematic review and meta-analysis","volume":"83","author":"Liu","year":"2024","journal-title":"Endocrine"},{"key":"10.1016\/j.autrev.2026.104121_bb0560","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1380654","article-title":"Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 treatments: a systematic review and meta-analysis of 19,139 multiple sclerosis patients","volume":"15","author":"Elgenidy","year":"2024","journal-title":"Front Neurol"},{"key":"10.1016\/j.autrev.2026.104121_bb0565","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14740338.2025.2574668","article-title":"Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 monoclonal antibodies: a systematic review and meta-analysis of observational studies","author":"Scavone","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.autrev.2026.104121_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105009","article-title":"Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: pathogenesis, risk of infection, and disease management","volume":"79","author":"Alvarez","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2026.104121_bb0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578066","article-title":"Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD","volume":"377","author":"Mears","year":"2023","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2026.104121_bb0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106257","article-title":"Comparing the efficacy and safety of extended vs standard dosing of ocrelizumab in MS: a systemic review and meta-analysis","volume":"94","author":"Baig","year":"2025","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"10.1016\/j.autrev.2026.104121_bb0585","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1474-4422(24)00140-6","article-title":"B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases","volume":"23","author":"Haghikia","year":"2024","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104121_bb0590","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.autrev.2026.104121_bb0595","author":"Kyverna Therapeutics"},{"key":"10.1016\/j.autrev.2026.104121_bb0600","author":"Cree"},{"issue":"4","key":"10.1016\/j.autrev.2026.104121_bb0605","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00125-023-06076-2","article-title":"Genetic engineering of regulatory T cells for treatment of autoimmune disorders including type 1 diabetes","volume":"67","author":"Tuomela","year":"2024","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.autrev.2026.104121_bb0610","doi-asserted-by":"crossref","first-page":"516","DOI":"10.2337\/db20-0421","article-title":"Peptidylarginine deiminase inhibition prevents diabetes development in NOD mice","volume":"70","author":"Sodr\u00e9","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2026.104121_bb0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174623","article-title":"Inhibition of PAD4-mediated NET formation by cl-amidine prevents diabetes development in nonobese diabetic mice","volume":"916","author":"Shen","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.autrev.2026.104121_bb0620","article-title":"Citrullination and PAD enzyme biology in type 1 diabetes - regulators of inflammation, autoimmunity, and pathology","volume":"12","author":"Yang","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104121_bb0625","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-023-02922-7","article-title":"BAFF blockade in experimental autoimmune encephalomyelitis reduces inflammation in the meninges and synaptic and neuronal loss in adjacent brain regions","volume":"20","author":"Gupta","year":"2023","journal-title":"J Neuroinflammation"},{"issue":"11","key":"10.1016\/j.autrev.2026.104121_bb0630","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.4049\/jimmunol.1700822","article-title":"Transient BAFF blockade inhibits type 1 diabetes development in nonobese diabetic mice by enriching immunoregulatory B lymphocytes sensitive to deletion by anti-CD20 cotherapy","volume":"199","author":"Wang","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104121_bb0635","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1362629","article-title":"A metformin add-on clinical study in multiple sclerosis to evaluate BRAIN remyelination and neurodegeneration (MACSiMiSE-BRAIN): study protocol for a multi-center randomized placebo controlled clinical trial","volume":"15","author":"De Keersmaecker","year":"2024","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2026.104121_bb0640","article-title":"The role of glucagon-like Peptide-1 agonists in the treatment of multiple sclerosis: a narrative review","volume":"16","author":"Kaye","year":"2024","journal-title":"Cureus"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T03:00:11Z","timestamp":1786071611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226001357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":130,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1568997226001357"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104121","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting shared immune pathways in multiple sclerosis and type 1 diabetes: Therapeutic insights from monoclonal antibodies","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104121","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104121"}}